Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinoic acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Retinoic acid. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-006379-65 Sponsor Protocol Number: 02A801 Start Date*: 2008-10-27
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease
    Medical condition: sperimentation only in patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003606-33 Sponsor Protocol Number: PK 2008 03 Start Date*: 2009-01-15
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Pilot study to investigate the feasibility of 13-cis-Retinoic acid pharmacokinetic monitoring in high-risk neuroblastoma
    Medical condition: High risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029260 Neuroblastoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004321-95 Sponsor Protocol Number: AMLSG 07-04 Start Date*: 2005-05-26
    Sponsor Name:University of Ulm
    Full Title: RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATI...
    Medical condition: newly diagnosed acute myeloid leukemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023409-37 Sponsor Protocol Number: AMLSG_15-10 Start Date*: 2011-03-02
    Sponsor Name:University Hospital Ulm
    Full Title: Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM...
    Medical condition: Adult patients (>60) with AML and NPM1 mutation ineligible for intensive chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005500-14 Sponsor Protocol Number: MZ-ATRACTION/ML 20804 Start Date*: 2007-09-05
    Sponsor Name:Universitätsmedizin der Johannes-Gutenberg Universität Mainz
    Full Title: A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGA...
    Medical condition: chronic HCV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019183 HCV LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002689-19 Sponsor Protocol Number: Allo-Relapse-2011 Start Date*: 2011-11-22
    Sponsor Name: [...]
    1.
    2. Haukeland University Hospital
    Full Title: TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: DISEASE STABILIZATION THROUGH CHEMOTHERAPY, IMMUNOMODULATORY TREATMENT AND IMMUNOTHERAPY
    Medical condition: Allotransplanted patients with early acute leukemia repse (within 1 year after transplant)
    Disease:
    Population Age: Adults Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004320-13 Sponsor Protocol Number: AMLSG 06-04 Start Date*: 2005-08-29
    Sponsor Name:Universitätsklinikum Ulm / University Clinical Center Ulm
    Full Title: RANDOMIZED PHASE III-STUDY ON VALPROIC ACID IN COMBINATION WITH ALL-TRANS RETINOIC ACID, STANDARD INDUCTION- AND CONSOLIDATION THERAPY IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
    Medical condition: newly diagnosed acute myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003959-21 Sponsor Protocol Number: BAP00731 Start Date*: 2007-09-25
    Sponsor Name:Basilea Pharmaceutica Ltd.
    Full Title: Open label treatment of patients with chronic hand dermatitis who have participated in a clincal trial involving oral alitretinoin
    Medical condition: Relapsed Chronic Hand Dermatitis (CHaD) Refractory to Topical Therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066695 Chronic hand dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004776-20 Sponsor Protocol Number: BAP00626 Start Date*: 2006-03-27
    Sponsor Name:Basilea Pharmaceutica Ltd
    Full Title: Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis
    Medical condition: Severe Chronic Hand Dermatitis (CHaD) Refractory to Topical Therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000421-39 Sponsor Protocol Number: AMLSG26-16/AML-ViVA Start Date*: 2017-02-03
    Sponsor Name:University Hospital Regensburg represented by Kaufmännischer Direktor
    Full Title: Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myelo...
    Medical condition: acute myeloid leukemia refractory to standard induction chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000972-15 Sponsor Protocol Number: 1002 Start Date*: 2004-09-03
    Sponsor Name:Michael Larsen
    Full Title: DIAMETIB
    Medical condition: Diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000432-85 Sponsor Protocol Number: BAP00091 Start Date*: 2004-08-05
    Sponsor Name:Basilea Pharmaceutica Ltd
    Full Title: Follow-up Efficacy and Safety Study of BAL4079 in the Treatment of Chronic Hand Dermatitis Refractory to Topical Therapy
    Medical condition: Severe Chronic Hand Dermatitis (CHaD) Refractory to Topical Therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001447-37 Sponsor Protocol Number: 52232 Start Date*: 2015-07-09
    Sponsor Name:University Medical Center Groningen
    Full Title: Efficacy of oral alitretinoin versus oral azathioprine in patients with severe chronic non-hyperkeratotic hand eczema. A randomized prospective open-label trial with blinded outcome assessment.
    Medical condition: Hand eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020212-11 Sponsor Protocol Number: 2010-338 Start Date*: 2010-09-09
    Sponsor Name:Overlæge dr.med. Frederik Grønhøj
    Full Title: Enkelt dosis (single dosis) farmakokinetik af 9-cis-retinoic acid (Alitretinoin, Toctino®) hos patienter med moderat til svær lever insufficiens.
    Medical condition: At undersøge enkeltdosis-farmakokinetikken af 9-cis-RA (Alitretinoin, Toctino®) og dets metaboliter hos patienter med moderat til svær leverinsufficiens og frivillige raske forsøgspersoner.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10024678 Liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003739-30 Sponsor Protocol Number: AMLSG 05-04 Start Date*: 2005-11-02
    Sponsor Name:Universitätsklinikum Ulm / University Clinical Center Ulm
    Full Title: Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM]
    Medical condition: primary refractory patients with acute myeloid leukemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001688-23 Sponsor Protocol Number: NA17598C Start Date*: 2004-10-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic em...
    Medical condition: symptomatic emphysema secondary to alpha-1-antitrypsin deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-009916-33 Sponsor Protocol Number: 00332/AMLSG14-09 Start Date*: 2011-05-13
    Sponsor Name:University Medical Center Freiburg
    Full Title: Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic...
    Medical condition: Patients older than 60 years with acute myeloid leukemia according to WHO (≥ 20 % blasts in the peripheral blood (pB) or bone marrow (BM)) not qualifying for, or not consenting to, standard remissi...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000345-38 Sponsor Protocol Number: BAP00089 Start Date*: 2004-07-13
    Sponsor Name:Basilea Pharmaceutica Ltd
    Full Title: Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis
    Medical condition: Severe Chronic Hand Dermatitis (CHaD) Refractory to Topical Therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004019-29 Sponsor Protocol Number: CRACCA-2019 Start Date*: 2021-07-15
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study.
    Medical condition: Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where it is contraindicated or refused by patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-005104-25 Sponsor Protocol Number: INV500 Start Date*: 2018-01-02
    Sponsor Name:Nova BioPharma Limited
    Full Title: Relative bioavailability and comparative pharmacokinetics of 13-CRA oral liquid and extracted capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in patients requi...
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029205 - Nervous system disorders 10029212 Nervous system neoplasms malignant NEC HLT
    20.0 10029205 - Nervous system disorders 10029211 Nervous system neoplasms malignant and unspecified NEC HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 19:44:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA